Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sangzhi alkaloid tablet plus NovoMix 30 for glycemic variability in type 2 diabetes
ChiCTR2200062688Phase 4Not yet recruiting
- Sponsor
- Zhu Xianyi Memorial Hospital
- Start
- Feb 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sangzhi total alkaloids in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Zhu Xianyi Memorial Hospital. Primary endpoint: Time in range over 24 hours. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
sangzhi total alkaloids
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2200062688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062688.